Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04826393 · ClinicalTrials.gov registry record · Phase 1
ASP8374 + Cemiplimab in Recurrent Glioma
A Phase 1 study of Glioblastoma and Recurrent Glioblastoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 4
- Study locations
NCT04826393 is a Phase 1 study of Glioblastoma and Recurrent Glioblastoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 14 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04826393, a Phase 1 study of Glioblastoma and Recurrent Glioblastoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is looking at the safety and efficacy of the drug combination of ASP8374 with cemiplimab in people with recurrent malignant glioma. The study will be conducted in two parts, the first portion of the study will be to establish the highest dose of ASP8374 that can be given safely with cemiplimab and will be used as the recommended dose of ASP8374 in combination with cemiplimab for the second portion of the study. The second portion of the study will be to compare the effect of having ASP8374 in combination with cemiplimab prior to surgery. The names of the study drugs involved in this study are: * ASP8374 * Cemiplimab
Conditions Studied
Interventions
- DRUG cemiplimab
- DRUG ASP8374
Study Locations (4)
Massachusetts
- Brigham and Women's Hospital - Boston
New York
- Columbia University Medical Center - New York
Ohio
- University of Cincinnati Medical Center - Cincinnati
Pennsylvania
- Hospital of the University of Pennsylvania, Abramson Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2024-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04826393
The ClinicalTrials.gov registry entry for NCT04826393 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (87% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which cemiplimab is the first listed.
NCT04826393 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT04826393 about?
NCT04826393 is a clinical study titled "ASP8374 + Cemiplimab in Recurrent Glioma". This study is looking at the safety and efficacy of the drug combination of ASP8374 with cemiplimab in people with recurrent malignant glioma. The study will be conducted in two parts, the first portion of the study will be to establish the highest dose of ASP8374 that can be given safely with cemi...
What is the current status of trial NCT04826393?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2022-03-09. Estimated completion is 2024-01-01.
What conditions does trial NCT04826393 study?
This clinical trial studies the following conditions: Glioblastoma, Recurrent Glioblastoma.
What interventions are being tested in trial NCT04826393?
The interventions under investigation include: cemiplimab (DRUG), ASP8374 (DRUG).
Who is sponsoring clinical trial NCT04826393?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04826393 being conducted?
This trial has 4 study locations across Massachusetts, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.